- Home
- MIRA vs CARM Comparison
MIRA vs CARM Comparison
Compare MIRA & CARM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRA
- CARM
- Stock Information
- Founded
- MIRA 2020
- CARM 2016
- Country
- MIRA United States
- CARM United States
- Employees
- MIRA N/A
- CARM N/A
- Industry
- MIRA Biotechnology: Pharmaceutical Preparations
- CARM Biotechnology: Pharmaceutical Preparations
- Sector
- MIRA Health Care
- CARM Health Care
- Exchange
- MIRA Nasdaq
- CARM Nasdaq
- Market Cap
- MIRA 19.5M
- CARM 16.4M
- IPO Year
- MIRA 2023
- CARM N/A
- Fundamental
- Price
- MIRA $1.54
- CARM $0.45
- Analyst Decision
- MIRA Strong Buy
- CARM Hold
- Analyst Count
- MIRA 2
- CARM 5
- Target Price
- MIRA $14.00
- CARM $0.90
- AVG Volume (30 Days)
- MIRA 3.0M
- CARM 2.8M
- Earning Date
- MIRA 08-12-2025
- CARM 08-07-2025
- Dividend Yield
- MIRA N/A
- CARM N/A
- EPS Growth
- MIRA N/A
- CARM N/A
- EPS
- MIRA N/A
- CARM N/A
- Revenue
- MIRA N/A
- CARM $19,964,000.00
- Revenue This Year
- MIRA N/A
- CARM N/A
- Revenue Next Year
- MIRA N/A
- CARM N/A
- P/E Ratio
- MIRA N/A
- CARM N/A
- Revenue Growth
- MIRA N/A
- CARM 32.45
- 52 Week Low
- MIRA $0.62
- CARM $0.14
- 52 Week High
- MIRA $5.01
- CARM $1.38
- Technical
- Relative Strength Index (RSI)
- MIRA 69.70
- CARM 56.21
- Support Level
- MIRA $1.07
- CARM $0.38
- Resistance Level
- MIRA $1.39
- CARM $0.42
- Average True Range (ATR)
- MIRA 0.13
- CARM 0.03
- MACD
- MIRA 0.02
- CARM -0.01
- Stochastic Oscillator
- MIRA 77.05
- CARM 89.89
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
About CARM Carisma Therapeutics Inc.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.